Understanding Pompe disease (glycogen storage disease type II), enzyme replacement therapy, next-generation treatments, respiratory and mobility management, clinical trials, and practical resources — organized by where you are in the journey.
This guide is not medical advice. It is an educational research summary written in plain language, drawn from published medical literature and clinical trial records. Every important decision must be made together with the patient’s medical team — metabolic specialists, neurologists, pulmonologists, and primary care doctors. Nothing here replaces those conversations. The purpose of this guide is to help patients and families walk into those conversations better prepared. This content does not create a doctor-patient relationship. Trouvera’s guides are produced using AI-assisted research synthesis with human editorial review; it is not written by treating physicians. Laws regarding medical information vary by jurisdiction; consult a local licensed professional for advice specific to your situation.
Standard care first. Every option discussed in this guide is intended as an addition to, not a replacement for, evidence-based standard treatments delivered by a qualified metabolic disease team. Pompe disease requires coordinated, multidisciplinary care from specialists experienced with lysosomal storage disorders.
Infantile-onset Pompe disease is a medical emergency. If your infant has been diagnosed with classic infantile-onset Pompe disease, enzyme replacement therapy must begin as soon as possible — ideally within days of diagnosis. Every week of delay worsens outcomes. Contact your metabolic specialist immediately.
Content last reviewed: May 2026 · Based on ACMG Pompe Disease Practice Guidelines (2006, updates pending), Pompe Disease Expert Working Group Recommendations, FDA prescribing information for Lumizyme, Nexviazyme, and Pombiliti+Opfolda, published clinical trial data (COMET, PROPEL, LOTS, LOPD Treatment Study), and medical literature · Always verify trial availability and treatment details with your medical team and primary sources.
⚡ Quick Start — If You Read Nothing Else
The 8 most important things to know right now.
Pompe disease is caused by a missing or deficient enzyme called GAA. Without enough acid alpha-glucosidase (GAA), glycogen accumulates in cells — especially in muscles — causing progressive weakness and organ damage.
There are two main forms: infantile-onset (IOPD) and late-onset (LOPD). Classic infantile-onset Pompe disease appears in the first months of life with severe heart and muscle involvement. Late-onset can appear at any age from childhood to adulthood and primarily affects skeletal and respiratory muscles.
Enzyme replacement therapy (ERT) is the foundation of treatment. Three FDA-approved ERTs exist: alglucosidase alfa (Lumizyme/Myozyme, approved 2006/2010), avalglucosidase alfa (Nexviazyme, approved 2021), and cipaglucosidase alfa + miglustat (Pombiliti+Opfolda, approved 2023).
Earlier treatment produces better outcomes. For infantile-onset Pompe, starting ERT before 6 months of age — ideally before symptoms appear — dramatically improves survival and motor milestones. This is why newborn screening matters.
Respiratory function must be monitored closely. Diaphragm weakness is a hallmark of Pompe disease. Many patients eventually need non-invasive ventilation (BiPAP), especially during sleep. Declining breathing function is often the most serious complication.
Gene therapy is in clinical trials and represents the future. Gene therapy programs (such as AT845, with others in development) aim to provide a lasting source of GAA production, potentially replacing lifelong infusions.
Multidisciplinary care is essential. Pompe disease affects muscles, breathing, heart, bones, and daily function. You need a team: metabolic specialist, neurologist, pulmonologist, cardiologist (especially for IOPD), physical therapist, occupational therapist, speech therapist, and nutritionist.
Get to a center with Pompe disease experience. This is a rare disease. Specialists at metabolic disease centers who see multiple Pompe patients will manage your care better than providers who have never treated it.
▼ Collapse
Understanding Pompe Disease
Pompe disease (also called glycogen storage disease type II, or GSD II) is a rare, inherited metabolic disorder caused by mutations in the GAA gene. This gene provides instructions for making an enzyme called acid alpha-glucosidase (GAA), which breaks down glycogen (stored sugar) inside cellular compartments called lysosomes.
When GAA is missing or not working properly, glycogen accumulates inside cells — particularly in muscle cells. Over time, this buildup damages muscles throughout the body, including the skeletal muscles used for movement, the diaphragm used for breathing, and (in the infantile form) the heart muscle.
Pompe disease is autosomal recessive, meaning a child must inherit two defective copies of the GAA gene (one from each parent) to develop the disease. Carriers (one working copy, one defective) are typically unaffected.
Estimated overall incidence: approximately 1 in 40,000 births
Infantile-onset Pompe disease (IOPD): approximately 1 in 138,000
Late-onset Pompe disease (LOPD): approximately 1 in 57,000
Incidence varies by ethnicity and region — higher prevalence reported in African American and Chinese populations
Over 600 different GAA gene mutations have been identified
Pompe disease affects all ethnicities and both sexes equally
Classic infantile-onset Pompe disease (IOPD): Presents within the first few months of life. Babies have very little or no GAA enzyme activity. Severe heart enlargement (hypertrophic cardiomyopathy), profound muscle weakness (floppy baby), feeding difficulties, and respiratory failure. Without treatment, most infants do not survive past 1–2 years. With early ERT, many survive into childhood and beyond.
Non-classic infantile-onset: Presents in the first year of life with muscle weakness but less severe or absent heart involvement. Some residual GAA activity remains.
Late-onset Pompe disease (LOPD): Can present at any age from childhood to late adulthood. Patients retain some residual GAA activity (typically 2–40% of normal). Progressive limb-girdle muscle weakness (difficulty climbing stairs, rising from chairs, walking) and respiratory muscle weakness (shortness of breath, sleep-disordered breathing) are the hallmarks. Heart involvement is rare in LOPD. Progression is highly variable — some patients remain ambulatory for decades, while others require wheelchairs and ventilators.
The most important concept in this guide: Pompe disease is treatable. Three FDA-approved enzyme replacement therapies exist, next-generation treatments are improving outcomes, and gene therapy trials are actively enrolling. Early diagnosis and early treatment produce the best results. If you or your child has been diagnosed, do not delay starting treatment.
Key Breakthroughs in Pompe Disease
The treatment landscape for Pompe disease has evolved significantly since the first ERT approval in 2006. Here are the most important advances:
FDA-APPROVED Alglucosidase alfa was the first enzyme replacement therapy for Pompe disease and fundamentally changed the natural history of the disease. In the pivotal trial for infantile-onset Pompe disease, ERT dramatically improved survival — most untreated infants died by age 1, while treated infants had significantly prolonged survival and improved motor and cardiac function. For late-onset patients, the LOTS trial demonstrated stabilization or improvement in walking distance and respiratory function. This remains widely used worldwide.
FDA-APPROVED Avalglucosidase alfa is a next-generation ERT engineered with high mannose-6-phosphate (M6P) content to improve cellular uptake. In the COMET trial — conducted in treatment-naive LOPD patients — avalglucosidase alfa improved respiratory function (FVC) more than alglucosidase alfa (a 2.43% greater increase in FVC% predicted at week 49). This met the pre-specified test for non-inferiority; the additional test for superiority narrowly missed statistical significance (p=0.063). It received FDA approval in August 2021 for late-onset Pompe disease and is now considered the preferred ERT by many specialists, particularly for treatment-naive patients.
FDA-APPROVED This two-component therapy combines a recombinant GAA enzyme (cipaglucosidase alfa, given by IV infusion) with an oral chaperone molecule (miglustat, taken before infusion) that stabilizes the enzyme and improves its delivery to muscles. In the PROPEL trial, this combination did not meet its primary endpoint (superiority over alglucosidase alfa on the 6-minute walk distance, p=0.072), but a key secondary endpoint showed a nominally significant respiratory (FVC) benefit. FDA approved it in September 2023 for adult LOPD patients (≥40 kg) who are not improving on their current ERT. The chaperone approach represents a novel strategy for improving ERT efficacy.
IMPLEMENTED IN MOST US STATES Pompe disease was added to the Recommended Uniform Screening Panel (RUSP) in the United States in 2015. As of 2026, the vast majority of US states include Pompe disease in their newborn screening panels. This has been transformative for infantile-onset Pompe disease: babies identified through screening can begin ERT before symptoms develop, leading to dramatically better outcomes compared to those diagnosed after symptoms appear. For LOPD, newborn screening identifies individuals who may not develop symptoms for years or decades, raising complex decisions about when to start treatment.
INVESTIGATIONAL Multiple gene therapy programs aim to provide a lasting source of GAA enzyme production by delivering a functional copy of the GAA gene. AT845 (Astellas, AAV-based, targeting muscle; FORTIS trial) is an active clinical program, and other AAV gene-therapy programs (including one developed by AskBio/Bayer) are in development. An earlier liver-directed program, SPK-3006 (Spark/Roche), was discontinued in 2024 after limited enrollment, illustrating how quickly this pipeline changes. Early clinical data from active programs show sustained GAA enzyme activity and potential for reducing or eliminating the need for ERT infusions. Gene therapy could fundamentally change Pompe disease management if trials succeed.
Diagnosis: The Tests You Need
Pompe disease diagnosis involves enzyme activity testing, genetic confirmation, and assessment of organ involvement. The earlier the diagnosis, the better the outcomes — especially for infantile-onset disease.
The primary diagnostic test measures acid alpha-glucosidase (GAA) enzyme activity. This can be performed on:
Dried blood spot (DBS): Screening test, used in newborn screening programs. Quick turnaround but must be confirmed with a second method if low.
Lymphocytes (white blood cells): More accurate than DBS. Low GAA activity in lymphocytes is highly suggestive of Pompe disease.
Skin fibroblasts: Considered the gold standard for enzyme activity measurement. Requires a skin biopsy and cell culture (takes 4–8 weeks for results).
Muscle biopsy: Can show glycogen accumulation and vacuolar myopathy but is no longer required for diagnosis in most cases.
Key point: IOPD patients typically have less than 1% of normal GAA activity. LOPD patients typically have 2–40% of normal activity. The amount of residual activity generally correlates with disease severity and age of onset.
Genetic testing of the GAA gene confirms the diagnosis and identifies the specific mutations. This is important because:
It confirms the diagnosis definitively
Certain mutations correlate with disease severity (e.g., the common c.-32-13T>G splice site mutation in European LOPD patients is associated with milder disease)
It enables genetic counseling for the family and carrier testing for relatives
CRIM status (cross-reactive immunologic material) can be predicted from the genotype — this determines whether the patient will produce any GAA protein, which affects the risk of developing immune responses to ERT
CRIM (Cross-Reactive Immunologic Material) status indicates whether the patient’s body makes any form of GAA protein, even if non-functional:
CRIM-positive: The body produces some GAA protein. The immune system partially recognizes ERT as “self” and is less likely to mount a strong immune response against it.
CRIM-negative: The body produces no GAA protein at all. The immune system treats ERT as completely foreign, often producing high levels of anti-drug antibodies that neutralize the enzyme and dramatically reduce its effectiveness. CRIM-negative patients require immune tolerance induction (ITI) before or at the start of ERT.
Why it matters: Approximately 25–30% of IOPD patients are CRIM-negative. Without ITI, these patients have poor outcomes despite ERT. CRIM testing should be completed before the first ERT infusion whenever possible.
At diagnosis, several assessments establish a baseline for monitoring disease progression and treatment response:
Pulmonary function tests (PFTs): FVC upright and supine (a drop of >10% from upright to supine suggests diaphragm weakness), MIP/MEP
Cardiac assessment: Echocardiogram (essential for IOPD; may be normal in LOPD), ECG
Muscle function: 6-minute walk test (6MWT), timed up-and-go, manual muscle testing, physical therapy assessment
Blood biomarkers: CK (creatine kinase, usually elevated), urinary glucose tetrasaccharide (Glc4, correlates with glycogen burden), liver enzymes (AST, ALT — may be elevated from muscle origin)
Imaging: MRI of thigh and paraspinal muscles (shows fat infiltration pattern), chest X-ray
Swallowing assessment: Particularly in IOPD and severely affected LOPD patients
Sleep study (polysomnography): To assess for nocturnal hypoventilation and sleep-disordered breathing
Key question for your specialist: “What is my GAA enzyme activity level, what are my specific GAA mutations, and what is my CRIM status? How do these results affect my treatment plan and expected course?”
Newborn Screening for Pompe Disease
Newborn screening (NBS) has transformed the detection of Pompe disease. By identifying affected individuals at birth — before symptoms develop — treatment can begin early enough to prevent irreversible damage.
A small blood sample (heel prick) is collected from every newborn, usually 24–48 hours after birth
The dried blood spot is tested for GAA enzyme activity
If activity is low, a second-tier test (often DNA sequencing of the GAA gene) is performed
Positive screens must be confirmed with repeat enzyme activity testing and genetic analysis
A positive newborn screen does NOT always mean disease — pseudodeficiency alleles (gene variants that lower enzyme activity in lab tests but do not cause disease) are common and can cause false positives
Referral to a metabolic disease specialist or geneticist
Confirmatory enzyme activity testing (lymphocytes or fibroblasts)
GAA gene sequencing to identify mutations
CRIM status determination (for IOPD)
Cardiac evaluation (echocardiogram, ECG)
Baseline muscle and respiratory assessments
Decision about when to start ERT: immediately for IOPD, or watchful monitoring for asymptomatic LOPD (this is an area of active debate among specialists)
What type of Pompe disease does my child (or I) have — infantile-onset or late-onset?
What is the GAA enzyme activity level, and what does it mean for disease severity?
What are the specific GAA gene mutations, and do they tell us anything about expected course?
What is the CRIM status, and does my child need immune tolerance induction?
Should ERT be started now, or is it safe to monitor and wait?
What baseline tests do I need before starting treatment?
Should family members be tested?
Are there any clinical trials I should consider?
Enzyme Replacement Therapy (ERT)
ERT is the foundation of Pompe disease treatment. It provides the missing GAA enzyme by intravenous infusion, typically every two weeks. Three FDA-approved options are now available.
FDA-APPROVED Approved for IOPD (Myozyme, 2006) and all ages (Lumizyme, 2010). Administered as an IV infusion at 20 mg/kg every 2 weeks. Infusions typically take 4–8 hours. Key trial results:
IOPD: In the pivotal trial, 13 of 18 treated infants were alive and ventilator-free at 18 months, compared to a historical survival rate of less than 20% without treatment
LOPD (LOTS trial): Stabilized or improved 6-minute walk distance (+25 meters vs. -3 meters placebo) and FVC (+1.2% predicted vs. -2.2% placebo) over 78 weeks
Infusion-associated reactions: Occur in up to 50% of patients over time. Symptoms include flushing, rash, fever, chills, nausea. Usually managed with premedications (antihistamines, antipyretics, steroids) and slower infusion rates
Anti-drug antibodies: Most patients develop antibodies to the enzyme. High sustained antibody titers (HSAT) can reduce efficacy, particularly in CRIM-negative IOPD patients
FDA-APPROVED Approved August 2021 for LOPD. Administered as an IV infusion at 20 mg/kg every 2 weeks. Engineered for improved cellular uptake through high mannose-6-phosphate content.
COMET trial results (head-to-head vs. alglucosidase alfa in LOPD):
FVC (primary endpoint): avalglucosidase alfa improved FVC by 2.43% predicted more than alglucosidase alfa at week 49 — meeting the test for non-inferiority (p=0.0074); the further test for superiority narrowly missed significance (p=0.063)
6-minute walk test: numerical improvement but not statistically significant at the primary timepoint
Consistently favored across multiple secondary endpoints including muscle strength
Safety profile similar to alglucosidase alfa
Many specialists now consider avalglucosidase alfa the preferred first-line ERT for LOPD based on the COMET trial results, though the magnitude of improvement over alglucosidase alfa is modest.
FDA-APPROVED Approved September 2023 for adult LOPD in patients weighing ≥40 kg who are not improving on their current enzyme replacement therapy (i.e., ERT-experienced; it is not approved for treatment-naive patients). This combines:
Cipaglucosidase alfa (Pombiliti): IV infusion of recombinant GAA enzyme, 20 mg/kg every 2 weeks
Miglustat (Opfolda): Oral capsule (65 mg) taken 1 hour before each infusion. Miglustat is a small molecule chaperone that stabilizes the enzyme, improving its half-life and delivery to muscle lysosomes
PROPEL trial results:
Primary endpoint (6-minute walk distance, tested for superiority): not met — cipaglucosidase alfa + miglustat improved walking distance by about +20.8 meters vs. +7.2 meters for alglucosidase alfa, a difference that did not reach statistical significance (p=0.072)
FVC (a key secondary endpoint): cipaglucosidase alfa + miglustat showed a roughly 3% greater change in predicted FVC versus alglucosidase alfa at week 52 (nominally significant, p=0.023)
FDA approval (September 2023) was based on the totality of the data, particularly the respiratory benefit in ERT-experienced patients
The chaperone concept (stabilizing enzyme with a small molecule) is a potentially important advance
Important: Miglustat for Pompe disease (Opfolda, 65 mg) is NOT the same as miglustat for Gaucher disease (Zavesca, 100 mg). Different doses, different indications — do not interchange.
CRIM-negative IOPD patients require immune tolerance induction to prevent the development of high-titer antibodies that neutralize ERT. The most widely used ITI protocol (developed at Duke University) combines:
Rituximab (anti-CD20 antibody)
Methotrexate
IVIG (intravenous immunoglobulin)
ITI is started at or before the first ERT infusion. Without ITI, CRIM-negative patients almost uniformly develop high sustained antibody titers (HSAT) that render ERT ineffective, leading to clinical decline and death despite treatment. With ITI, many CRIM-negative patients achieve immune tolerance and have outcomes approaching those of CRIM-positive patients.
ERT is a lifelong commitment. Each infusion takes 4–8 hours and must be repeated every 2 weeks for the rest of the patient’s life (unless gene therapy or another approach replaces it in the future). Missing infusions leads to clinical decline. Infusions may be given at a hospital, infusion center, or — for stable patients — at home through home infusion services.
Which ERT is recommended for me (or my child), and why?
Am I CRIM-negative, and do I need immune tolerance induction?
What is my current antibody titer against the enzyme?
Can I receive infusions at home?
What should I do if I develop an infusion reaction?
How often will my respiratory and muscle function be re-tested?
Should I consider switching to a newer ERT if I am on alglucosidase alfa?
Am I eligible for any gene therapy trials?
Is a higher dose of ERT appropriate for my situation?
What biomarkers do you use to track whether treatment is working?
Next-Generation & Emerging Treatments
While ERT has been life-changing, its limitations — incomplete muscle penetration, immune responses, and the burden of biweekly infusions — drive ongoing research into improved and alternative approaches.
INVESTIGATIONAL Rather than replacing the missing enzyme, substrate reduction therapy aims to reduce the amount of glycogen produced, decreasing the load on the impaired enzyme. This approach is being explored as an adjunct to ERT rather than a replacement.
Small molecule chaperones bind to misfolded GAA enzyme and help it fold correctly, allowing residual enzyme to function better. Miglustat (in the Pombiliti+Opfolda combination) works as an enzyme stabilizer for exogenous ERT. Future chaperones may enhance the patient’s own residual enzyme activity, particularly in LOPD patients who retain some GAA production. This is a promising area of research for patients with specific mutations that produce a misfolded but partially functional enzyme.
INVESTIGATIONAL Research has shown that impaired autophagy (the cell’s recycling system) is a major contributor to muscle damage in Pompe disease — not just glycogen accumulation alone. Autophagy dysfunction leads to accumulation of cellular debris, damaged mitochondria, and lipofuscin. Therapies targeting autophagy pathways are in early research stages. This represents a potential paradigm shift in understanding why ERT alone does not fully reverse muscle damage.
Gene Therapy for Pompe Disease
Gene therapy aims to deliver a functional copy of the GAA gene to the body’s cells, potentially providing a lasting source of enzyme production and eliminating the need for lifelong biweekly infusions.
INVESTIGATIONAL AT845 uses an adeno-associated virus (AAV8) vector to deliver the GAA gene directly to muscle cells. It is administered as a single IV infusion. Phase 1/2 clinical trial data in LOPD patients showed sustained GAA enzyme activity in muscle, improvements in respiratory function, and the potential to reduce or discontinue ERT in some patients. Key considerations include the need for immunosuppression to prevent immune responses against the viral vector, and the unknown long-term durability of gene expression. Verify current trial status on ClinicalTrials.gov.
INVESTIGATIONAL SPK-3006 uses an AAV vector to deliver the GAA gene to liver cells, which then secrete functional GAA enzyme into the bloodstream for systemic distribution. This “liver as a factory” approach leverages the liver’s natural secretory capacity. An advantage of liver-directed gene therapy is the potential for inducing immune tolerance to GAA protein, which could reduce antibody-related complications. However, Roche discontinued the SPK-3006 program in 2024 (the RESOLUTE trial, NCT04093349, enrolled only a few patients before enrollment was halted). It is described here for context; liver-directed gene therapy for Pompe is now being pursued by other developers (for example, an AskBio/Bayer program).
Gene therapy reality check. Gene therapy for Pompe disease is promising but not yet approved. Key unknowns include: how long gene expression will last (will patients need re-dosing?), the full safety profile of high-dose AAV vectors, whether pre-existing antibodies to AAV will prevent treatment in some patients, and the risk of liver inflammation (hepatotoxicity). If you are interested in gene therapy, discuss clinical trial eligibility with your metabolic specialist.
Respiratory Management
Respiratory failure is the leading cause of morbidity and mortality in Pompe disease. The diaphragm — the primary breathing muscle — is particularly vulnerable to glycogen accumulation. Monitoring and managing respiratory function is as important as ERT itself.
Forced vital capacity (FVC): Measured sitting and lying down. A drop of >10% from upright to supine indicates diaphragm weakness. Should be tested every 6 months.
Maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP): Measure respiratory muscle strength. More sensitive than FVC for detecting early weakness.
Polysomnography (sleep study): Detects nocturnal hypoventilation and sleep apnea, which often develop before daytime respiratory symptoms. Recommended at diagnosis and annually thereafter.
Pulse oximetry: Overnight home oximetry can screen for desaturations during sleep between formal sleep studies.
Many Pompe disease patients eventually require ventilatory support, initially during sleep and potentially progressing to daytime use:
BiPAP (bilevel positive airway pressure): The most common form of NIV for Pompe disease. Provides higher pressure during inhalation and lower pressure during exhalation, assisting the weakened diaphragm.
Indications for starting NIV: FVC <50% predicted, supine FVC drop >25%, documented nocturnal hypoventilation (CO2 >50 mmHg or sustained O2 desaturation <88%), symptoms (morning headaches, excessive daytime sleepiness, shortness of breath lying down)
Key point: Starting NIV early — before respiratory failure develops — preserves quality of life and may slow decline. NIV should not be seen as a last resort.
Weak respiratory muscles impair the ability to cough effectively, increasing the risk of pneumonia and mucus plugging:
Mechanical insufflation-exsufflation (CoughAssist): A device that helps simulate a cough by first inflating the lungs and then rapidly switching to negative pressure. Essential for patients with peak cough flow <270 L/min.
Respiratory physiotherapy: Techniques including lung volume recruitment (breath stacking), assisted cough, and postural drainage.
Vaccinations: Annual influenza and pneumococcal vaccines are critical. COVID-19 vaccination as recommended. Respiratory infections can be life-threatening in Pompe patients with compromised breathing.
What is my FVC in upright and supine positions, and what does the difference mean?
Should I have a sleep study to check for nighttime breathing problems?
Do I need BiPAP or other ventilatory support?
Am I at risk for respiratory failure during anesthesia or illness?
What should I do if I get a respiratory infection?
Should I have a CoughAssist device?
What vaccinations should I receive?
Mobility & Rehabilitation
Progressive proximal muscle weakness — particularly in the hips, thighs, and trunk — is a hallmark of Pompe disease. Rehabilitation plays a crucial role in maintaining function and independence.
Moderate aerobic exercise is safe and recommended. Swimming, walking, and stationary cycling at moderate intensity improve cardiovascular fitness and may slow muscle deconditioning without damaging muscles. Avoid extreme exertion.
Supervised strength training: Low-to-moderate resistance exercises can maintain or improve strength. Should be designed by a physical therapist experienced with neuromuscular diseases.
Stretching and flexibility: Regular stretching prevents contractures, particularly in hip flexors and ankle plantar flexors.
Aquatic therapy: Buoyancy of water supports weakened muscles while allowing exercise. Particularly beneficial for Pompe patients.
Avoid: High-intensity eccentric exercise, which can accelerate muscle damage in metabolic myopathies.
Ankle-foot orthoses (AFOs): For foot drop, which is common in LOPD
Canes, walkers, and rollators: For balance and fall prevention
Wheelchairs and power scooters: For community mobility when walking distance declines significantly
Stairlifts and home modifications: Ramps, grab bars, raised toilet seats, shower chairs
Occupational therapy: For adapting daily activities (dressing, cooking, driving) to changing abilities
What exercises are safe for me?
Should I see a physical therapist specializing in neuromuscular diseases?
Would I benefit from any assistive devices?
Are there precautions I need for anesthesia if I need surgery?
How should I manage falls?
Nutrition & Diet
Nutrition plays a supportive role in Pompe disease management. While no diet can replace ERT, optimizing nutrition can help maintain muscle mass and overall health.
High-protein diet: Some specialists recommend a high-protein diet (25–30% of calories from protein) to support muscle maintenance. Evidence is limited but the rationale is sound for patients with progressive myopathy.
Adequate caloric intake: Avoiding both overweight (which burdens weakened muscles) and underweight (which accelerates muscle wasting) is important.
IOPD feeding: Many IOPD babies require specialized feeding support, including high-calorie formula, nasogastric tube feeding, or gastrostomy tube placement due to feeding difficulties, swallowing problems, and failure to thrive.
Vitamin D and calcium: Osteoporosis is common in Pompe disease due to reduced mobility and muscle weakness. Adequate vitamin D and calcium intake is recommended.
Swallowing assessment: Dysphagia (swallowing difficulty) can develop in both IOPD and LOPD. Speech-language pathology evaluation is recommended if choking, coughing during meals, or unexplained weight loss occurs.
Pregnancy, Fertility & Family Planning
Pompe disease is autosomal recessive: it is caused by changes (variants) in the GAA gene, and a person develops Pompe only when they inherit a disease-causing variant from both parents. If both partners are carriers, each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier (unaffected) child, and a 25% chance of a child with two working copies.
Genetic counseling and carrier testing. If you have Pompe disease or a family history, genetic counseling is recommended before pregnancy. Your partner can be offered GAA carrier testing to clarify the risk to children. Prenatal testing and, for some families, preimplantation genetic testing (PGT) with IVF are options to discuss.
Newborn screening. Pompe disease is now part of newborn screening in many US states. Early detection matters most for infantile-onset Pompe (IOPD), where starting enzyme replacement therapy (ERT) as early as possible substantially improves outcomes. Let your obstetric and pediatric teams know about any family history so the baby’s result is reviewed promptly.
ERT during pregnancy. For a woman with Pompe disease, enzyme replacement therapy (alglucosidase alfa or avalglucosidase alfa) is generally continued during pregnancy when it is clinically indicated. Untreated Pompe can worsen during pregnancy — the growing uterus and increased oxygen demand add stress to already-weakened breathing and core muscles — so stopping ERT is not automatically safer. Data are limited, and decisions should be individualized with your specialist; the Pompe Registry collects pregnancy outcomes to guide care.
Breathing and mobility. Pregnancy increases the work of breathing. Women with respiratory involvement should have lung function and, where relevant, nighttime ventilation reviewed before and during pregnancy. A maternal-fetal medicine (high-risk obstetrics) specialist should co-manage the pregnancy together with your Pompe/neuromuscular team.
Questions to ask your doctor:
Should my partner be tested as a GAA carrier, and would genetic counseling help us plan?
If I become pregnant, will I continue enzyme replacement therapy, and how will it be monitored?
How will my breathing be assessed and supported during pregnancy and delivery?
Will my baby be checked through newborn screening for Pompe, and how soon are results available?
class="content-section" data-stage="living">
Clinical Trials — Finding and Enrolling
Clinical trials are particularly important in Pompe disease because the treatment landscape is still evolving. Gene therapy trials represent the most transformative potential advance since the first ERT approval.
Trial / Program
Agent(s)
Population
Status / NCT
COMET (pivotal)
Avalglucosidase alfa vs. alglucosidase alfa
LOPD, ERT-naive
Completed; basis of Nexviazyme approval (NCT02782741)
PROPEL (pivotal)
Cipaglucosidase alfa + miglustat vs. alglucosidase alfa
LOPD, ERT-experienced
Completed; basis of Pombiliti+Opfolda approval (NCT03729362)
Note: Gene therapy trial status changes frequently. Always verify current enrollment status and eligibility at ClinicalTrials.gov or through your metabolic disease center. NCT numbers for gene therapy trials should be confirmed before enrollment decisions.
ClinicalTrials.gov (clinicaltrials.gov): Search “Pompe disease” and filter by status (recruiting), location, and intervention type.
Acid Maltase Deficiency Association (AMDA): Patient advocacy organization that maintains information about current trials.
International Pompe Association (IPA): Global advocacy network with trial information.
Your metabolic disease center: Academic metabolic centers often run or participate in trials not widely advertised.
Sanofi Genzyme patient services: For information about Lumizyme, Nexviazyme, and related trials.
Amicus Therapeutics patient services: For information about Pombiliti+Opfolda and related programs.
International Access & Regulatory Landscape
ERT availability varies globally, and access remains a challenge in many countries due to the extremely high cost of enzyme replacement therapy.
Cost: ERT for Pompe disease can cost $300,000–$800,000+ per year per patient, making it one of the most expensive therapies in medicine. Insurance coverage, government programs, and manufacturer patient assistance programs are essential.
NICE (UK): Has issued technology appraisals for ERT in Pompe disease with specific eligibility criteria; access may require meeting specific functional thresholds.
Developing countries: Access to ERT remains extremely limited in many low- and middle-income countries due to cost.
Manufacturer patient assistance: Sanofi Genzyme (for Lumizyme/Nexviazyme) and Amicus Therapeutics (for Pombiliti+Opfolda) offer patient assistance programs for eligible patients.
Failed & De-Adopted Therapies
Understanding what has been tried and did not work helps patients and families evaluate new claims and avoid unproven treatments.
DE-ADOPTED Early in the ERT era, some CRIM-negative IOPD patients were treated with ERT alone, without ITI. Nearly all developed high sustained antibody titers that neutralized the enzyme, leading to clinical decline and death despite treatment. This approach is now considered inadequate — ITI is mandatory for CRIM-negative patients starting ERT.
INSUFFICIENT Some early studies explored lower doses of alglucosidase alfa (5–10 mg/kg). Clinical experience demonstrated that 20 mg/kg every 2 weeks is the minimum effective dose for most patients, and some IOPD patients may benefit from even higher doses (40 mg/kg every 2 weeks). Subtherapeutic dosing leads to inadequate glycogen clearance.
FAILED Before ERT was available, various dietary approaches (high-protein diets, amino acid supplementation, alanine supplementation) were tried as primary therapy. While a high-protein diet may provide modest supportive benefit, dietary therapy alone does not halt disease progression and cannot substitute for enzyme replacement. Diet is a supplement to, not a replacement for, ERT.
Why this matters: If someone suggests one of these abandoned approaches, or claims that supplements, herbs, or alternative therapies can replace ERT, be skeptical. Always ask your metabolic specialist: “Is there evidence from clinical trials that this works in Pompe disease?”
class="content-section" data-stage="resources">
Specialty Centers
Pompe disease is rare, and outcomes are better when managed by specialists who have experience with lysosomal storage disorders. A metabolic disease center with multiple Pompe patients will provide better coordinated care than a provider who has seen the disease only once or twice.
No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.
University of Utah — Division of Medical Genetics
Metabolic disease program with lysosomal storage disorder expertise
Location: 50 N Medical Dr, Salt Lake City, UT 84132 Phone: 801-581-2121 Programs: Metabolic disease clinic, genetic counseling, ERT infusion services, neuromuscular evaluation, clinical trial referrals. ARUP Laboratories (University of Utah) provides GAA enzyme activity testing and genetic testing for Pompe disease.
Primary Children’s Hospital — Intermountain Health
Pediatric metabolic disease and genetics program
Location: 100 N Mario Capecchi Dr, Salt Lake City, UT 84113 Phone: 801-662-1000 Programs: Pediatric metabolic disease, genetics, neuromuscular evaluation, ERT infusion for pediatric patients. Coordinates with the University of Utah for specialized testing.
Huntsman Cancer Institute (HCI) — University of Utah
Location: 2000 Circle of Hope Dr, Salt Lake City, UT 84112 Phone: 801-585-0303 Note: While primarily an oncology center, HCI coordinates with the University of Utah genetics division and ARUP Laboratories for enzyme and genetic testing.
Intermountain Health — Neuromuscular Program
Phone: 801-442-2000 Programs: Neuromuscular disease evaluation, pulmonary function testing, rehabilitative services across the Intermountain Health system.
How to choose.University of Utah Medical Genetics = primary metabolic disease center with enzyme/genetic testing through ARUP. Primary Children’s = pediatric patients. Both coordinate care for Pompe patients in the Mountain West region.
Information verified May 2026. Availability changes — confirm with each institution directly.
Duke University Medical Center — Division of Medical Genetics
Location: Durham, NC · Phone: 919-684-2036
One of the world’s leading Pompe disease centers. Pioneered immune tolerance induction (ITI) protocols for CRIM-negative IOPD. Led by physicians with extensive Pompe experience. Active gene therapy and next-generation ERT research. The Duke Pompe Disease Program has treated more IOPD patients than virtually any other center.
Erasmus MC / Pompe Center — University Medical Center Rotterdam
Location: Rotterdam, Netherlands (listed under US National for reference as international center of excellence) · Note: The Erasmus MC Pompe Center is the world’s oldest and largest Pompe disease research program. Led by the team that developed the first ERT. See International section for details.
University of Florida — Powell Gene Therapy Center
Location: Gainesville, FL · Phone: 352-273-8990
Leading gene therapy research for Pompe disease. Active clinical trials. Extensive preclinical and translational research program.
NIH National Institute of Neurological Disorders and Stroke (NINDS)
Location: Bethesda, MD · Phone: 301-496-5751
Research protocols for Pompe disease, including natural history studies and investigational therapies. NIH Clinical Center.
Cincinnati Children’s Hospital Medical Center
Location: Cincinnati, OH · Phone: 513-636-4200
Lysosomal storage disorder program with Pompe disease expertise. Pediatric ERT infusion center.
Emory University — Division of Medical Genetics
Location: Atlanta, GA · Phone: 404-778-8500
Lysosomal storage disease program. Clinical genetics and metabolic disease expertise.
VA Neuromuscular Disease & Metabolic Care
The VA system can provide ERT and neuromuscular care for veterans with Pompe disease. Given the rarity of the condition, the VA typically coordinates with academic metabolic disease centers through community care arrangements.
Request referral to an academic center with Pompe disease experience
ERT infusions may be arranged through VA infusion services or community care authorization
Pulmonary function testing and ventilatory support are available through VA pulmonology
George E. Wahlen VA Medical Center (Salt Lake City): 801-582-1565 VA Community Care: 1-877-881-7618
The Hospital for Sick Children (SickKids), Toronto
Location: 555 University Avenue, Toronto, ON M5G 1X8 Phone: 416-813-1500 Programs: Division of Clinical and Metabolic Genetics. Pediatric Pompe disease management, ERT infusion, genetic counseling.
BC Children’s Hospital / Vancouver General Hospital
Location: Vancouver, BC Phone: 604-875-2345 Programs: Adult and pediatric metabolic disease programs, biochemical genetics laboratory.
McGill University Health Centre (MUHC), Montreal
Location: Montréal, QC Phone: 514-934-1934 Programs: Medical genetics division with lysosomal storage disorder expertise.
Canadian Fabry/LSD Research and Treatment: Specialized provincial programs exist for lysosomal storage disorders including Pompe disease; contact your provincial genetics center. Canadian Organization for Rare Disorders (CORD):raredisorders.ca · 1-877-302-7273
International Centers of Excellence for Pompe Disease
Erasmus MC — Pompe Center, Rotterdam, Netherlands: The world’s oldest and largest Pompe disease center, founded by the team that developed the first ERT. Extensive clinical and research programs. Contact: +31-10-703-6985
National Hospital for Neurology and Neurosurgery, Queen Square, London, UK: MRC Centre for Neuromuscular Diseases. Adult Pompe disease program with ERT and clinical trials.
Universitätsklinikum München (LMU), Munich, Germany: Friedrich-Baur-Institut. Neuromuscular disease center with metabolic myopathy expertise.
Hôpital Raymond-Poincaré, Garches, France: French national reference center for neuromuscular diseases.
National Center for Child Health and Development, Tokyo, Japan: Pediatric metabolic disease program.
Caregiver Guidance
Caring for someone with Pompe disease is a long-term commitment that spans years and decades. The biweekly infusion schedule, respiratory equipment management, mobility assistance, and emotional burden require sustained support.
Each infusion takes 4–8 hours. Plan work and family schedules around this every-other-week commitment.
Home infusion may be available for stable patients, reducing travel and clinic time. Ask your metabolic team about eligibility.
Keep emergency medications accessible (epinephrine auto-injector, diphenhydramine) in case of infusion reactions.
Track symptoms systematically: Keep a log of infusion reactions, energy levels, respiratory symptoms, and functional changes to share with the medical team.
Learn how to set up, clean, and troubleshoot BiPAP machines and CoughAssist devices
Have backup equipment and supplies available (extra masks, filters, tubing)
Battery backup for ventilators in case of power outages
Know who to call for equipment problems — durable medical equipment (DME) company emergency line
Connect with other Pompe families: The Acid Maltase Deficiency Association (AMDA) and International Pompe Association (IPA) offer peer support, educational resources, and community.
Respite care: For caregivers of children with severe IOPD, respite services provide temporary relief. Contact your state’s early intervention or disability services program.
Financial assistance: ERT costs are catastrophic without insurance. Manufacturer patient assistance programs, rare disease foundations, and state programs may help. The National Organization for Rare Disorders (NORD) at 1-800-999-6673 offers financial assistance information.
Advance care planning: For progressive cases, discuss goals of care with the medical team while the patient can participate in decisions.
Glossary
AAV (adeno-associated virus)
A small virus used as a delivery vehicle (vector) for gene therapy. Does not cause disease in humans.
Acid alpha-glucosidase (GAA)
The enzyme deficient in Pompe disease. Normally breaks down glycogen inside lysosomes.
Anti-drug antibodies
Immune proteins the body produces against ERT enzymes. High levels can neutralize the treatment.
Autosomal recessive
A pattern of inheritance requiring two copies of a mutated gene (one from each parent) to cause disease.
BiPAP
Bilevel positive airway pressure. A non-invasive ventilator that assists breathing through a mask, providing different pressures for inhalation and exhalation.
Chaperone therapy
Use of small molecules that help misfolded enzymes achieve their correct shape, improving function. Miglustat (Opfolda) is a chaperone used in Pompe disease.
CK (creatine kinase)
A muscle enzyme released into the blood when muscles are damaged. Usually elevated in Pompe disease.
CRIM (cross-reactive immunologic material)
Refers to whether the body produces any form of GAA protein. CRIM-negative patients have no native GAA and are at high risk of immune reaction to ERT.
ERT (enzyme replacement therapy)
Treatment that provides the missing GAA enzyme by IV infusion. The standard of care for Pompe disease.
FVC (forced vital capacity)
The total amount of air you can forcefully exhale after a full breath. Used to track respiratory function in Pompe disease.
GAA gene
The gene that provides instructions for making the GAA enzyme. Mutations in this gene cause Pompe disease.
Glycogen
A stored form of sugar (glucose) used by cells for energy. In Pompe disease, glycogen accumulates because it cannot be broken down properly.
HSAT (high sustained antibody titer)
Persistent high levels of antibodies against ERT that significantly reduce treatment effectiveness.
Hypertrophic cardiomyopathy
Thickening of the heart muscle. A hallmark of infantile-onset Pompe disease.
IOPD (infantile-onset Pompe disease)
The most severe form, presenting in the first months of life with heart, muscle, and respiratory involvement.
ITI (immune tolerance induction)
A protocol using immunosuppressive drugs to prevent the body from making antibodies against ERT. Required for CRIM-negative patients.
LOPD (late-onset Pompe disease)
The form presenting from childhood to adulthood, primarily affecting skeletal and respiratory muscles.
Lysosome
A cellular compartment (organelle) that acts as the cell’s recycling center. GAA enzyme normally functions inside lysosomes.
M6P (mannose-6-phosphate)
A sugar tag on enzymes that directs them into lysosomes. Avalglucosidase alfa is engineered with high M6P content for improved uptake.
NIV (non-invasive ventilation)
Breathing support delivered through a mask rather than a tube in the throat. BiPAP is the most common form.
Pseudodeficiency allele
A gene variant that lowers enzyme activity in laboratory tests but does not cause disease. An important cause of false-positive newborn screens.
Sources and Further Reading
This guide draws on published medical literature, clinical trial records, prescribing information, and expert guidelines. Key sources are listed below.
ACMG Practice Guidelines: Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267–288.
Pompe Disease Expert Working Group: Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45(3):319–333.
LOTS Trial: van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med. 2010;362(15):1396–1406.
COMET Trial: Diaz-Manera J, Kishnani PS, Kushlaf H, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET). Lancet Neurol. 2021;20(12):1012–1026. (NCT02782741)
PROPEL Trial: Schoser B, Roberts M, Goemans N, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL). Lancet Neurol. 2023;22(12):1098–1111. (NCT03729362)
CRIM and ITI: Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13(8):729–736.
Newborn Screening: Chien YH, Lee NC, Thurberg BL, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009;124(6):e1116–e1125.
External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.
Key Search Terms for ClinicalTrials.gov and PubMed
“AAV gene therapy glycogen storage disease type II”
“Pompe disease autophagy”
“chaperone therapy lysosomal storage disease”
A practical test for any online claim: If a website is making a claim about Pompe disease treatment that does not appear anywhere in PubMed or GeneReviews, that should be a significant warning sign.
What This Guide Does Not Know
An honest guide names its own limits:
This guide cannot diagnose or treat anyone. It does not know your specific GAA mutations, enzyme activity level, CRIM status, respiratory function, or personal circumstances. Only your medical team can build an actual treatment plan.
Pompe disease research is evolving. Gene therapy trials, new ERT formulations, and improved understanding of disease mechanisms are advancing rapidly. Every time-sensitive fact should be re-verified with your team, on FDA.gov, and on ClinicalTrials.gov.
Drug approvals and availability vary by country. This guide focuses primarily on FDA-approved therapies. Access differs in Europe, Asia, Canada, and other regions.
Individual outcomes are highly variable. Even patients with the same mutations can have very different disease courses. The amount of residual enzyme activity, modifying genes, and other factors contribute to this variability.
Specialized care makes a difference. Referral to a metabolic disease center with Pompe disease experience is often the single highest-value step a patient can take.
A final word. A Pompe disease diagnosis is overwhelming. But you are living in the best era yet for this disease. Three approved enzyme replacement therapies, gene therapy trials actively enrolling, newborn screening identifying patients earlier than ever, and a global community of patients, families, and researchers all working toward better treatments. Get to a metabolic disease center. Start ERT early. Stay engaged with your medical team. Connect with other families. Help is real. Use it.
Important Safety Information: Enzyme Replacement Therapy (ERT)
Pompe disease is treated with enzyme replacement therapy (ERT) — alglucosidase alfa (Lumizyme/Myozyme), avalglucosidase alfa (Nexviazyme), or cipaglucosidase alfa + miglustat (Pombiliti + Opfolda). All ERT products are given by intravenous (IV) infusion and share important safety considerations.
ERT infusion reactions — Serious warnings:
Infusion-associated reactions (IARs) and anaphylaxis: Infusion reactions are the most common serious side effect of ERT. They can range from mild (flushing, urticaria/hives, rash, chills, fever) to severe (hypotension, anaphylaxis, respiratory distress, bronchospasm). Severe reactions can occur even in patients who have tolerated many previous infusions. Infusions are given in a monitored clinical setting where anaphylaxis can be treated.
Pre-medication: Antihistamines, antipyretics, and sometimes corticosteroids are typically given before infusions to reduce the frequency and severity of reactions. Follow your treatment center's pre-medication protocol.
Slowing the infusion rate: If mild to moderate reactions occur, slowing the infusion rate often allows it to be completed. Severe reactions (anaphylaxis) require immediate discontinuation and emergency treatment.
Antibody development (CRIM-negative patients): Some patients (particularly infantile Pompe disease patients who are cross-reactive immunologic material-negative, or CRIM-negative) develop high levels of antibodies to the infused enzyme, which can significantly reduce its effectiveness. Immune tolerance induction (ITI) protocols using rituximab or other immunosuppressants may be used in CRIM-negative patients before or alongside ERT to prevent this. Discuss CRIM status with your metabolic specialist.
Infusion frequency: ERT is given every 2 weeks as an IV infusion, typically lasting several hours. The time commitment is significant; plan for 4–8+ hours per visit including pre-medication, infusion, and post-infusion observation. Home infusion is available at some centers for stable patients.
Respiratory monitoring in Pompe disease:
Pompe disease causes progressive respiratory muscle weakness. Even if you feel well, regular pulmonary function testing (spirometry, upright and supine FVC) is essential — respiratory failure can develop insidiously. Your pulmonologist should assess you at least every 6 months.
Nocturnal non-invasive ventilation (BiPAP) is often needed before daytime breathing difficulty becomes apparent, because the diaphragm is particularly vulnerable. If you snore, wake unrested, or have morning headaches, discuss a sleep study with your team.
Respiratory infections (flu, COVID-19, RSV, pneumonia) can cause acute severe deterioration in Pompe disease. Stay up to date on all recommended vaccines. Have a written action plan from your pulmonologist for how to manage respiratory illnesses.